This really isn't true - aducanumab works very well at what it was designed to do - clear beta amyloid plaque from the brain. What is unknown at this stage is if this will prevent the cognitive decline of Alzheimer's patients.
The FDA was given an updated mandate in 2016 to be aggressive in approving neurology drugs on the basis of proxy biomarkers. This is what they have done.
My gut feeling is any truly effective Alzheimers treatment is going to have to combine anti-tau and anti-beta amyloid treatments and be started very early. This approval allows both combination trials to be run and the treatment of very early stage patients.
This really isn't true - aducanumab works very well at what it...
-
- There are more pages in this discussion • 215 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.00 |
Change
0.010(1.01%) |
Mkt cap ! $1.141B | |||
| Open | High | Low | Value | Volume |
| $1.01 | $1.01 | 94.3¢ | $8.618M | 8.821M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 43508 | $1.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.01 | 34138 | 2 |
View Market Depth
| Last trade - 16.10pm 01/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |